NCT03433469 (2023) was a phase II trial that showed that patients with resectable, stage I-IIIA EGFR-mutated NSCLC who received up to 8 weeks of neoadjuvant osimertinib (80 mg daily) had a MPR in 4 (15%) of 27 patients, 0 PCRs, and nodal downstaging in 4 (44%) of 9 patients (48). Here, EGFR is linked to non-small cell lung carcinoma.